Intra Cellular Buy Hold or Sell Recommendation

ITCI -- USA Stock  

USD 20.80  0.17  0.82%

Given the investment horizon of 30 days, and your above average risk tolerance our recommendation regarding Intra Cellular Therapies is 'Strong Sell'. Macroaxis provides Intra Cellular buy hold or sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding ITCI positions. The advice algorithm takes into account all of Intra Cellular Thera available fundamental, technical, and predictive indicators you will find on this site. The advice is provided from ITCI buy-and-hold prospective. Please also check Intra Cellular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus.

Time Horizon

Risk Tolerance

Symbol
Execute Advice
Sell Intra CellularBuy Intra Cellular
Strong Sell

Volatility

Hype Condition

Current Valuation

Odds of Distress

Economic Sensitivity

Analyst Consensus

Piotroski F Score

Financial Leverage

Inapplicable
For the selected time horizon Intra Cellular Therapies has a mean deviation of 1.92, semi deviation of 2.45, standard deviation of 2.84, variance of 8.06, downside variance of 7.73 and semi variance of 6.0
Macroaxis buy or sell recommendations module can be used to complement current analysts and expert consensus on Intra Cellular Therapies. Our buy, hold, or sell recommendation engine utilizes analyzes the firm potential to grow using all fundamental data market data available at the time. To make sure Intra Cellular Therapies is not overpriced, please check out all Intra Cellular fundamentals including its Net Income, Earnings Per Share, Current Liabilities, as well as the relationship between Current Ratio and Total Asset . Given that Intra Cellular Thera has Price to Earning of 6.56 times, we strongly advise you confirm Intra Cellular Thera market performance and probability of bankruptcy to make sure the company can sustain itself in the current economic cycle given your regular risk tolerance and investing horizon.

Intra Cellular Thematic Classifications

Biotech IdeaBiotech
Biotechnology and pharmaceuticals production and services

Returns Distribution Density

Mean Return0.30Value At Risk5.15
Potential Upside5.23Standard Deviation2.84
 Return Density 
      Distribution 

Institutional Investors

Security TypeSharesValue
Rhenman Partners Asset Management AbCommon Shares697 K12.3 M
Franklin Street Advisors IncCommon Shares54.1 K955 K
Essex Investment Management Co LlcCommon Shares32 K565 K
Fox Run Management LlcCommon Shares30.2 K533 K
Gemmer Asset Management LlcCommon Shares10 K177 K
Bank Of MontrealCommon Shares5.6 K100 K
Fny Investment Advisers LlcCommon Shares5008 K
Fny Investment Advisers LlcPut Options5.00.0
Dld Asset Management LpCall Options1 M21.5 M

Intra Cellular Greeks

α
Alpha over DOW
=0.59
β
Beta against DOW=2.57
σ
Overall volatility
=2.58
Ir
Information ratio =0.06

Intra Cellular Volatility Alert

Intra Cellular Therapies currently demonstrates below average downside deviation of 2.78. It has Information Ratio of 0.06 and Jensen Alpha of 0.59. However, we do advice investors to further question Intra Cellular Therapies expected returns to make sure all indicators are consistent with the current outlook about its relatively low value at risk.
    
 Better Than Average     
    
 Worse Than Average Compare Intra Cellular to competition

Intra Cellular Fundamental Vs Peers

FundamentalsIntra CellularPeer Average
Return On Equity(27.39) % (15.17) %
Return On Asset(17.14) % (15.64) %
Current Valuation673.88 M152.14 B
Shares Outstanding54.7 M1.43 B
Shares Owned by Insiders12.24 % 6.91 %
Shares Owned by Institutions81.19 % 18.37 %
Number of Shares Shorted3.53 M3.24 M
Price to Earning6.56 times40.69 times
Price to Book2.62 times14.44 times
Revenue150.55 K9.85 B
Gross Profit(79.17 M)21.75 B
EBITDA(111.92 M)1.41 B
Net Income(106.32 M)517.71 M
Cash and Equivalents437.01 M3.89 B
Cash per Share7.99 times5.17 times
Debt to Equity0.31 % 0.72 %
Current Ratio22.55 times3.30 times
Book Value Per Share7.74 times13.64 times
Cash Flow from Operations(91.08 M)1.25 B
Short Ratio12.97 times2.09 times
Earnings Per Share2.17 times2.30 times
Number of Employees4910.67 K
Beta0.950.34
Market Capitalization1.11 B29.78 B
Total Asset542.57 M126.86 B
Retained Earnings(193.05 M)38.24 B
Working Capital401.13 M3.58 B
Current Asset541.82 M36.8 B
Current Liabilities140.69 M33.34 B
   Intra Cellular exotic insider transaction detected [view details]

Intra Cellular Alerts

Trading Alerts and Improvement Suggestions
The company reported previous year revenue of 150.55 K. Net Loss for the year was (106.32 M) with loss before overhead, payroll, taxes, and interest of (79.17 M).
Intra-Cellular Th currently holds about 437.01 M in cash with (91.08 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 7.99.
Over 81.0% of the company shares are owned by institutional investors
Latest headline from www.mareainformativa.com: Intra-Cellular Therapies Inc Receives 29.10 Consensus Price Target from Brokerages
Please also check Intra Cellular Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with current analyst consensus. Please also try Portfolio Suggestion module to get suggestions outside of your existing asset allocation including your own model portfolios.
vendors/bower_components/jquery.easy-pie-chart/dist/jquery.easypiechart.min.js">